Developer docs
API playgroundTry for free, no card

Search company profiles

Algae4IBD Consortium

Full company profile

uuid00sobre

Namestring
Algae4IBD Consortium
Legal namestring
Algae4IBD Consortium
Websiteurl
algae4ibd.eu
Company typeenum
Private
Founded yearint
2021
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersQiryat Shemona, Israel
HQ citystring
Qiryat Shemona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
algae biotechnology, functional food research, pharmaceutical research, bioactive compounds, gut inflammation research
Industry5 codes
PRIMARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYEUABAIAJ
Biological CO₂ Utilization (algae/biotech conversion to fuels, chemicals, proteins)
Energy, Utilities & Environment/Carbon & Climate Solutions (Carbon Markets, Offsets, CCS/CCUS)/CO₂ Utilization & Carbon-to-Value (E-fuels, Chemicals, Building Materials)
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYAFAJAKAF
Prebiotics & Dietary Fibers (Inulin, FOS/GOS, Resistant Starch, Beta-Glucan, Psyllium)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYAFAEAAAE
Seaweed & Algae Aquaculture (incl. microalgae)
Agriculture & Food Production/Animal Production & Aquaculture/Aquaculture (Fish & Shellfish Farming)
NAICS code1 code
  • Aquaculture11251
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biotechnology Research Services
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1EU Horizon 2020 Research Funding
TypeLicensing Royalties
Description

The Algae4IBD project received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement N° 101000501. This is a non-dilutive research grant funding the 4-year project duration.

algae4ibd.eu
2Research Partnership Services
TypeProfessional Services
Description

The consortium provides research services through collaboration with academic partners, hospitals, and companies for algae cultivation, extraction, food development, and pharmaceutical development across 11 countries.

algae4ibd.eu
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details7 tiers
1Early Bird Summit Ticket
ModelOtherBilling cadenceOne time/ perpetual license
Notes

150 EUR - available until 15th January 2026

algae4ibd.eu
2Late Registration Summit Ticket
ModelOtherBilling cadenceOne time/ perpetual license
Notes

170 EUR - available until 31st January 2026

algae4ibd.eu
3Conference Dinner
ModelOtherBilling cadenceOne time/ perpetual license
Notes

100 EUR - takes place on 4th March 2026

algae4ibd.eu
4Excursion to Howth
ModelOtherBilling cadenceOne time/ perpetual license
Notes

80 EUR - takes place on 6th March 2026

algae4ibd.eu
5Exhibition Booth (Standard)
ModelOtherBilling cadenceOne time/ perpetual license
Notes

700 EUR - includes booth and 1 conference pass

algae4ibd.eu
6Exhibition Booth (Premium)
ModelOtherBilling cadenceOne time/ perpetual license
Notes

750 EUR - includes booth and 2 conference passes

algae4ibd.eu
7Summer School Fee
ModelOtherBilling cadenceOne time/ perpetual license
Notes

610 EUR per person - includes accommodation, lab utilities, daily lunch, visits, and Saturday group activity. Lab insurance of approximately 50 EUR extra if home university insurance doesn't cover activities abroad. Equivalent to 6.5 ECTS.

algae4ibd.eu
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Algae4IBD
Description

EU Horizon 2020 research project studying algae and their metabolites to develop functional foods and medications for IBD treatment

algae4ibd.eu
+2 more records
Core offering1 text field

The Algae4IBD Consortium is a multi-partner research collaboration that screens algae strains for bioactive compounds with anti-inflammatory, antioxidant, pain-relieving, and prebiotic properties, and develops them into functional food prototypes and pharmaceutical leads for inflammatory bowel disease (IBD). The consortium produces research outputs including the Interactive Bioactive Algae Map covering 187 algae strains, algae-enriched food prototypes, scientific publications, and educational resources.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 55%+ of algae strains showed anti-inflammatory activity in testing
+5 more records
Product overview1 text field

Algae4IBD is a research consortium (not a commercial product company) focused on developing algae-based solutions for inflammatory bowel disease (IBD). The consortium is conducting research to identify bioactive compounds from 187 algae strains and develop them into functional foods (such as algae-enriched pesto, butter, chocolates, and gummy bears) and novel pharmaceuticals. Key outputs include the Interactive Bioactive Algae Map (a research database), recipe booklets, factsheets, and scientific publications. The project has 21 partners across 11 countries and aims to deliver solutions by mid-2026, shortening development time from research to market from 10 to 4 years.

Product and service4 records
1Interactive Bioactive Algae Map
CategoryResearch Database
Description

A free interactive web map cataloguing 187 algae strains and their potential health-beneficial properties including anti-inflammatory, antioxidant, pain-relieving, and prebiotic activities, available to researchers, industry stakeholders, and interested users.

2Algae-Enriched Food Prototypes
CategoryFunctional Food Prototypes
Description

Functional food prototypes incorporating algae extracts, including pesto, butter, vegan brownies, fairy cakes, savory cookies, plant-based spreads, confectionery, gummy bears, and chocolates, developed as research outputs to demonstrate the feasibility of algae-enriched functional foods.

3Algae Recipe Booklet
CategoryEducational Resource
Description

A downloadable recipe booklet featuring algae-based recipes including butter, tapenade, foccacia, pesto, chocolate, cakes, gummy bears, vegan burrata, and vegan cheese, accompanied by background information about algae.

4Algae-Based Therapeutics Research Program
CategoryPharmaceutical Research
Description

A multi-disciplinary research program investigating algae compounds for the prevention and treatment of pain, inflammation, and inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, with the goal of shortening the development timeline from research to market from 10 to 4 years.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership15 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Irish agricultural and food development authority. Dr. Maria Hayes from Teagasc serves as senior researcher and local organizer of the Algae for Health Summit. Hosted taste testing trials at Teagasc Food Research Center in Dublin and developed algae-enriched food prototypes including pesto, baked goods, spreads, and confectionery.

2Wiley
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Global publishing company sponsoring best talk and best poster prizes (150 EUR each) at the Algae for Health in Food and Pharma Summit.

algae4ibd.eu
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Funded the Networking Initiative for the Algae for Health Summit under the Marine Research Programme with support from the Government of Ireland.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

National Tourism Development Authority of Ireland. Provided financial support for the Algae for Health in Food and Pharma Innovation & Industry Summit.

5MIGAL Galilee Research Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-06-01
Description

The coordinating institution for the Algae4IBD consortium, led by Dr. Dorit Avni who serves as Project Coordinator. MIGAL brings expertise in inflammation and immune system research. Located in Israel, they initiated the project and assembled experts from 11 countries to pursue the EU Horizon 2020 grant.

algae4ibd.eu
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

ESC gGmbH manages the Algae4IBD website and handles all project communication and dissemination activities on behalf of the consortium. Based in Oldenburg, Germany. Dr. Melanie Maria Obermeier serves as Media, Press and Communication contact.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Centre of Marine Sciences at the University of Algarve in Portugal. Prof. Luísa Barreira leads algae research working with microalgae for 14 years. Hosted the summer school in July 2024 and contributes expertise in microalgae cultivation and bioactive compound discovery.

8Necton
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Europe's oldest microalgae producer, located in Portugal. Mariana Carneiro serves as Innovation Manager, optimizing cultivation of microalgae for various applications. Operates industrial-scale production with tubular photo-bioreactors of 19,000+ liters. Contributes to understanding scaling challenges and sustainable production methods.

algae4ibd.eu
9InnCoCells
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

EU Horizon 2020 project within the AIMS-cluster. Scientists are looking for new cosmetic ingredients that can nurture the skin microbiome or heal skin inflammation, prospecting plants and residues from agri-food industry.

algae4ibd.eu
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

EU Horizon 2020 project within the AIMS-cluster. Researchers focus on marine microbiomes from sponges, microalgae, and fish, studying molecules with antifungal or antimicrobial properties for disease protection in aquaculture, agriculture, and human health.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

EU Horizon 2020 project within the AIMS-cluster. Scientists aim to develop molecules with tailor-made properties for oncology, cosmetics, pharmaceutics, and agriculture by identifying unexploited compounds in marine and extremophilic microorganisms using experimental machine learning.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Italian hospital contributing clinical expertise. Dr. Federica Ungaro introduced patient biopsy-based assays for IBD, providing clinically relevant platforms to accelerate translation of research findings.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

French algae company. Dr. Benoit Quéguineur serves as Partnership Manager. Developed encapsulation technology for algal extracts and contributed to food prototype development including algae-enriched products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Israeli algae production company. Dr. Amikam Bar-Gil contributes expertise in microalgae cultivation and strain optimization. Believes in the big potential of algae industry and anticipates increased investment in startups if the project succeeds.

15AIMS-cluster (Algae4IBD, InnCoCells, MARBLES, SECRETed)
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

A collaborative cluster of four EU Horizon 2020 funded projects sharing know-how and tackling common challenges. InnCoCells looks for cosmetic ingredients, MARBLES focuses on marine microbiomes for aquaculture and agriculture, and SECRETed develops molecules for oncology, cosmetics, and pharmaceuticals. The cluster aims to benefit individual project outcomes and increase collective reach.

algae4ibd.eu
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major probiotics and food cultures producer with established gut-health and microbiome offerings. Comparable end-application focus on gut health and bioactive functional ingredients, though using bacterial cultures rather than algae.

TypeDirect peer
Description

Clinical-stage biotech developing microbiome-derived therapeutics for inflammatory bowel disease and other immune-mediated diseases. Directly comparable to Algae4IBD's goal of using bioactives to modulate the gut microbiome in IBD, with both pursuing novel non-steroidal, non-biologic mechanisms.

TypeDirect peer
Description

Clinical-stage microbiome therapeutics company developing defined bacterial consortia (including candidates for IBD). Comparable in targeting gut microbiome modulation in IBD via rationally designed biological interventions rather than algae-derived small molecules.

TypeBroad incumbent
Description

Global nutrition and health ingredients giant with functional food, microbiome, and prebiotic offerings (including HMO prebiotics). Comparable in combining microbiome science with ingredient commercialization for IBD-adjacent gut health applications.

TypeEmerging player
Description

Clinical-stage microbiome company developing phage-based therapeutics for microbiome-related diseases including IBD. Partially comparable: targets gut microbiome modulation in IBD using a different modality (phage) but converging on the same biology Algae4IBD seeks to modulate.

TypeDirect peer
Description

Microbiome drug discovery company using high-resolution microbiome analysis to identify therapeutic candidates for IBD and other immune conditions. Compares to Algae4IBD's screening approach for identifying bioactive compounds that influence inflammation and gut health.

TypeBroad incumbent
Description

Global leader in algae fermentation and functional ingredients (including post-Pioneer Algae acquisition). Comparable industrial algae scale-up and functional ingredient development capabilities relevant to Algae4IBD's产业化 ambitions.

TypeBroad incumbent
Description

Established seaweed-based functional ingredient producer supplying extracts for human nutrition, animal feed, and agriculture. Comparable in extracting bioactives from seaweeds/macroalgae for health applications, though serving a broader end-market than IBD.

TypeDirect peer
Description

Microbiome therapeutics company (formerly 4D Pharma) with a focus on inflammatory bowel disease using live biotherapeutics. Comparable target disease and gut-focused mechanism, though 4D uses bacterial strains rather than algae-derived bioactives.

TypeDirect peer
Description

Algae-based nutraceutical and natural product company producing spirulina and astaxanthin for health applications. Compares to Algae4IBD's algae cultivation and bioactive compound discovery, though focused on nutritional rather than IBD-specific positioning.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Algae4IBD Consortium

Biotechnology Research Servicesalgae4ibd.eu

Algae4IBD Consortium firmographics

Firmographics
Name
Algae4IBD Consortium
Legal name
Algae4IBD Consortium
Website
https://algae4ibd.eu
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Algae4IBD Consortium industry classification

Industry
Product category
Biotechnology Research Services
NAICS
Aquaculture (11251)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAAAFAG
Microbiome Modulating Small Molecules & Antibiotic Alternatives
SECONDARYEUABAIAJ
Biological CO₂ Utilization (algae/biotech conversion to fuels, chemicals, proteins)
Energy, Utilities & Environment/Carbon & Climate Solutions (Carbon Markets, Offsets, CCS/CCUS)/CO₂ Utilization & Carbon-to-Value (E-fuels, Chemicals, Building Materials)
SECONDARYAFAJAKAE
Probiotics (Strains, Spore-Formers, Synbiotic Components)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYAFAJAKAF
Prebiotics & Dietary Fibers (Inulin, FOS/GOS, Resistant Starch, Beta-Glucan, Psyllium)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
SECONDARYAFAEAAAE
Seaweed & Algae Aquaculture (incl. microalgae)
Agriculture & Food Production/Animal Production & Aquaculture/Aquaculture (Fish & Shellfish Farming)

Keywords

  • Algae biotechnology
  • Functional food research
  • Pharmaceutical research
  • Bioactive compounds
  • Gut inflammation research

Where Algae4IBD Consortium is headquartered

Location

Headquarters

HQ city
Qiryat Shemona
HQ country
Israel
HQ region
Middle East

Offices4 records

Markets served

Algae4IBD Consortium business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. EU Horizon 2020 Research Funding: The Algae4IBD project received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement N° 101000501. This is a non-dilutive research grant funding the 4-year project duration.
  2. Research Partnership Services: The consortium provides research services through collaboration with academic partners, hospitals, and companies for algae cultivation, extraction, food development, and pharmaceutical development across 11 countries.

Pricing tiers

ModelBillingPrice
OtherOne time/ perpetual licenseEarly Bird Summit Ticket
OtherOne time/ perpetual licenseLate Registration Summit Ticket
OtherOne time/ perpetual licenseConference Dinner
OtherOne time/ perpetual licenseExcursion to Howth
OtherOne time/ perpetual licenseExhibition Booth (Standard)
OtherOne time/ perpetual licenseExhibition Booth (Premium)
OtherOne time/ perpetual licenseSummer School Fee

Go-to-market motion3 records

Distribution channels4 records

Marketing channels10 records

Algae4IBD Consortium product offering

Product offering

Core offering

The Algae4IBD Consortium is a multi-partner research collaboration that screens algae strains for bioactive compounds with anti-inflammatory, antioxidant, pain-relieving, and prebiotic properties, and develops them into functional food prototypes and pharmaceutical leads for inflammatory bowel disease (IBD). The consortium produces research outputs including the Interactive Bioactive Algae Map covering 187 algae strains, algae-enriched food prototypes, scientific publications, and educational resources.

Product overview

Algae4IBD is a research consortium (not a commercial product company) focused on developing algae-based solutions for inflammatory bowel disease (IBD). The consortium is conducting research to identify bioactive compounds from 187 algae strains and develop them into functional foods (such as algae-enriched pesto, butter, chocolates, and gummy bears) and novel pharmaceuticals. Key outputs include the Interactive Bioactive Algae Map (a research database), recipe booklets, factsheets, and scientific publications. The project has 21 partners across 11 countries and aims to deliver solutions by mid-2026, shortening development time from research to market from 10 to 4 years.

Differentiator

Problem solved

Functional benefit

Brands

  • Algae4IBD: EU Horizon 2020 research project studying algae and their metabolites to develop functional foods and medications for IBD treatment
  • AIMS-cluster
  • Algae4IBD Talks

Products and services

  • Interactive Bioactive Algae Map A free interactive web map cataloguing 187 algae strains and their potential health-beneficial properties including anti-inflammatory, antioxidant, pain-relieving, and prebiotic activities, available to researchers, industry stakeholders, and interested users.
  • Algae-Enriched Food Prototypes Functional food prototypes incorporating algae extracts, including pesto, butter, vegan brownies, fairy cakes, savory cookies, plant-based spreads, confectionery, gummy bears, and chocolates, developed as research outputs to demonstrate the feasibility of algae-enriched functional foods.
  • Algae Recipe Booklet A downloadable recipe booklet featuring algae-based recipes including butter, tapenade, foccacia, pesto, chocolate, cakes, gummy bears, vegan burrata, and vegan cheese, accompanied by background information about algae.
  • Algae-Based Therapeutics Research Program A multi-disciplinary research program investigating algae compounds for the prevention and treatment of pain, inflammation, and inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, with the goal of shortening the development timeline from research to market from 10 to 4 years.

Quantifiable outcome

  • 55%+ of algae strains showed anti-inflammatory activity in testing
  • +5 more outcomes

Companies that use Algae4IBD Consortium

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Algae4IBD Consortium technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Algae4IBD Consortium partnerships and signals

Strategic signal

Partnerships

15 partnerships are on record, tiered core, minor and major.

  • TeagasccoreStrategic or Co-development Partner · 1 March 2026Irish agricultural and food development authority. Dr. Maria Hayes from Teagasc serves as senior researcher and local organizer of the Algae for Health Summit. Hosted taste testing trials at Teagasc Food Research Center in Dublin and developed algae-enriched food prototypes including pesto, baked goods, spreads, and confectionery.
  • WileyminorStrategic or Co-development Partner · 1 January 2026Global publishing company sponsoring best talk and best poster prizes (150 EUR each) at the Algae for Health in Food and Pharma Summit.
  • Marine Institute (Ireland)majorStrategic or Co-development Partner · 1 January 2025Funded the Networking Initiative for the Algae for Health Summit under the Marine Research Programme with support from the Government of Ireland.
  • Fáilte IrelandmajorStrategic or Co-development Partner · 1 January 2025National Tourism Development Authority of Ireland. Provided financial support for the Algae for Health in Food and Pharma Innovation & Industry Summit.
  • MIGAL Galilee Research InstitutecoreStrategic or Co-development Partner · 1 June 2021The coordinating institution for the Algae4IBD consortium, led by Dr. Dorit Avni who serves as Project Coordinator. MIGAL brings expertise in inflammation and immune system research. Located in Israel, they initiated the project and assembled experts from 11 countries to pursue the EU Horizon 2020 grant.
  • European Science Communication Institute (ESCI)coreStrategic or Co-development Partner · 1 January 2021ESC gGmbH manages the Algae4IBD website and handles all project communication and dissemination activities on behalf of the consortium. Based in Oldenburg, Germany. Dr. Melanie Maria Obermeier serves as Media, Press and Communication contact.
  • CCMAR - Centre of Marine SciencescoreStrategic or Co-development Partner · 1 January 2021Centre of Marine Sciences at the University of Algarve in Portugal. Prof. Luísa Barreira leads algae research working with microalgae for 14 years. Hosted the summer school in July 2024 and contributes expertise in microalgae cultivation and bioactive compound discovery.
  • NectoncoreStrategic or Co-development Partner · 1 January 2021Europe's oldest microalgae producer, located in Portugal. Mariana Carneiro serves as Innovation Manager, optimizing cultivation of microalgae for various applications. Operates industrial-scale production with tubular photo-bioreactors of 19,000+ liters. Contributes to understanding scaling challenges and sustainable production methods.
  • InnCoCellsmajorStrategic or Co-development Partner · 1 January 2021EU Horizon 2020 project within the AIMS-cluster. Scientists are looking for new cosmetic ingredients that can nurture the skin microbiome or heal skin inflammation, prospecting plants and residues from agri-food industry.
  • MARBLESmajorStrategic or Co-development Partner · 1 January 2021EU Horizon 2020 project within the AIMS-cluster. Researchers focus on marine microbiomes from sponges, microalgae, and fish, studying molecules with antifungal or antimicrobial properties for disease protection in aquaculture, agriculture, and human health.
  • SECRETedmajorStrategic or Co-development Partner · 1 January 2021EU Horizon 2020 project within the AIMS-cluster. Scientists aim to develop molecules with tailor-made properties for oncology, cosmetics, pharmaceutics, and agriculture by identifying unexploited compounds in marine and extremophilic microorganisms using experimental machine learning.
  • San Raffaele HospitalcoreStrategic or Co-development Partner · 1 January 2021Italian hospital contributing clinical expertise. Dr. Federica Ungaro introduced patient biopsy-based assays for IBD, providing clinically relevant platforms to accelerate translation of research findings.
  • AlgaiacoreStrategic or Co-development Partner · 1 January 2021French algae company. Dr. Benoit Quéguineur serves as Partnership Manager. Developed encapsulation technology for algal extracts and contributed to food prototype development including algae-enriched products.
  • Yemoja LtdcoreStrategic or Co-development Partner · 1 January 2021Israeli algae production company. Dr. Amikam Bar-Gil contributes expertise in microalgae cultivation and strain optimization. Believes in the big potential of algae industry and anticipates increased investment in startups if the project succeeds.
  • AIMS-cluster (Algae4IBD, InnCoCells, MARBLES, SECRETed)majorStrategic or Co-development Partner · 1 January 2020A collaborative cluster of four EU Horizon 2020 funded projects sharing know-how and tackling common challenges. InnCoCells looks for cosmetic ingredients, MARBLES focuses on marine microbiomes for aquaculture and agriculture, and SECRETed develops molecules for oncology, cosmetics, and pharmaceuticals. The cluster aims to benefit individual project outcomes and increase collective reach.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Algae4IBD Consortium competitors and assessment

Company assessment

Broad incumbents

  • Chr. Hansen (now Novonesis): Major probiotics and food cultures producer with established gut-health and microbiome offerings. Comparable end-application focus on gut health and bioactive functional ingredients, though using bacterial cultures rather than algae.
  • DSM-Firmenich: Global nutrition and health ingredients giant with functional food, microbiome, and prebiotic offerings (including HMO prebiotics). Comparable in combining microbiome science with ingredient commercialization for IBD-adjacent gut health applications.
  • Corbion: Global leader in algae fermentation and functional ingredients (including post-Pioneer Algae acquisition). Comparable industrial algae scale-up and functional ingredient development capabilities relevant to Algae4IBD's产业化 ambitions.
  • Acadian Seaplants: Established seaweed-based functional ingredient producer supplying extracts for human nutrition, animal feed, and agriculture. Comparable in extracting bioactives from seaweeds/macroalgae for health applications, though serving a broader end-market than IBD.

Direct peers

  • Enterome: Clinical-stage biotech developing microbiome-derived therapeutics for inflammatory bowel disease and other immune-mediated diseases. Directly comparable to Algae4IBD's goal of using bioactives to modulate the gut microbiome in IBD, with both pursuing novel non-steroidal, non-biologic mechanisms.
  • Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia (including candidates for IBD). Comparable in targeting gut microbiome modulation in IBD via rationally designed biological interventions rather than algae-derived small molecules.
  • Microbiotica: Microbiome drug discovery company using high-resolution microbiome analysis to identify therapeutic candidates for IBD and other immune conditions. Compares to Algae4IBD's screening approach for identifying bioactive compounds that influence inflammation and gut health.
  • 4D Pharma (now BiomeBank): Microbiome therapeutics company (formerly 4D Pharma) with a focus on inflammatory bowel disease using live biotherapeutics. Comparable target disease and gut-focused mechanism, though 4D uses bacterial strains rather than algae-derived bioactives.
  • Cyanotech: Algae-based nutraceutical and natural product company producing spirulina and astaxanthin for health applications. Compares to Algae4IBD's algae cultivation and bioactive compound discovery, though focused on nutritional rather than IBD-specific positioning.

Emerging players

  • BiomX: Clinical-stage microbiome company developing phage-based therapeutics for microbiome-related diseases including IBD. Partially comparable: targets gut microbiome modulation in IBD using a different modality (phage) but converging on the same biology Algae4IBD seeks to modulate.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Algae4IBD Consortium social profiles

Digital presence

Algae4IBD Consortium financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Algae4IBD Consortium leadership team

Management profile

Number of profiles

Profiles2 records

Algae4IBD Consortium funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Algae4IBD Consortium M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Algae4IBD Consortium

What does Algae4IBD Consortium do?

The Algae4IBD Consortium is a multi-partner research collaboration that screens algae strains for bioactive compounds with anti-inflammatory, antioxidant, pain-relieving, and prebiotic properties, and develops them into functional food prototypes and pharmaceutical leads for inflammatory bowel disease (IBD). The consortium produces research outputs including the Interactive Bioactive Algae Map covering 187 algae strains, algae-enriched food prototypes, scientific publications, and educational resources.

Is Algae4IBD Consortium a public or private company?

Algae4IBD Consortium is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Algae4IBD Consortium founded?

Algae4IBD Consortium was founded in 2021. It employs 51 to 100 people.

Where is Algae4IBD Consortium based?

Algae4IBD Consortium is headquartered in Qiryat Shemona, Israel, in the Middle East region.

How does Algae4IBD Consortium make money?

Two revenue lines are on record. EU Horizon 2020 Research Funding is the primary driver. The others are research Partnership Services.

Who are Algae4IBD Consortium's main competitors?

Broad incumbents on record are Chr. Hansen (now Novonesis), DSM-Firmenich, Corbion and Acadian Seaplants. Direct peers are Enterome, Vedanta Biosciences, Microbiotica, 4D Pharma (now BiomeBank) and Cyanotech. BiomX is listed as an emerging player.

Does Algae4IBD Consortium have an API?

No public API is recorded for Algae4IBD Consortium.

What industry is Algae4IBD Consortium in?

Algae4IBD Consortium's product category is Biotechnology Research Services. Its primary akta.pro industry code is HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives, with a secondary code of EUABAIAJ, Biological CO₂ Utilization (algae/biotech conversion to fuels, chemicals, proteins). Its NAICS code is 11251 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales